Compare
Nuvaxovid vs. Comirnaty

Nuvaxovid (Novavax COVID-19 vaccine) is a recombinant vaccine. It's used to prevent infection from the virus that causes COVID-19. Nuvaxovid is FDA approved for adults 65 years of age and older. It's also approved for people ages 12 to 64 years with at least one risk factor for severe problems from COVID. This vaccine is given as an injection in the muscle by a trained healthcare professional. It's given as an updated Nuvaxovid booster shot each year to help protect against the latest strains of the COVID virus. Side effects include tiredness, headache, and pain and tenderness at the injection site.

• Prevention of COVID-19 infection in people 65 years of age and older
• Prevention of COVID-19 infection in people ages 12 to 64 years old with at least one condition that puts them at high risk of serious problems from illness

• Tenderness at the injection site
• Pain at the injection site
• Muscle pain
• Headache
• Tiredness
• Feeling unwell

• Allergic reaction
• Heart inflammation (swelling)
• Possible fainting after vaccination
• Lowered response to Nuvaxovid in people with a weakened immune system

Comirnaty (Pfizer COVID-19 vaccine) is an mRNA vaccine that's used to prevent infection from the virus that causes COVID-19. It's FDA approved for people 65 years and older, and for children and adults ages 5 to 64 years old who have at least one risk factor for severe COVID. The vaccine is given as a single booster shot into the muscle by a healthcare professional. Common side effects include pain at the injection site, tiredness, headache, and chills.

• Prevention of COVID-19 infection in people 65 years of age and older
• Prevention of COVID-19 infection in people ages 5 to 64 years old with at least one condition that puts them at high risk of serious problems from illness

People 12 years and older:

• Pain at the injection site (up to 91%)
• Tiredness (up to 78%)
• Headache (up to 76%)
• Chills (up to 50%)
• Muscle pain (up to 46%)
• Joint pain (up to 28%)
• Fever (up to 24%)
• Swelling at the injection site (up to 12%)
• Redness at the injection site (up to 10%)

People ages 5 to 11 years old:

• Pain at the injection site (up to 84%)
• Tiredness (up to 52%)
• Headache (up to 38%)
• Redness at the injection site (up to 26%)
• Swelling at the injection site (up to 20%)
• Muscle pain (up to 18%)
• Chills (up to 13%)
• Fever (up to 8%)
• Joint pain (up to 8%)

• Heart inflammation (swelling)
• Possible fainting after vaccination
• Lowered response to Comirnaty in people with weakened immune systems